Stilla Technologies is a Paris-based European biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing biologists with tools for high-resolution genetic analysis.
Stilla Technologies has been providing research organizations specialized in molecular biology and genetic analysis.
Stilla Technologies was co-founded in 2013 by Rémi Dangla. The company is headquartered in Villejuif, France, with an office in Beverly, Massachusetts.
Stilla has developed the Naica system, an innovative digital PCR platform compatible with multiple chemistries and equipped with multiplex capabilities. Most of all, by encapsulating all steps for digital PCR in a single chip, Naica offers a fast and user friendly solution, rendering digital PCR accessible to all.
Stilla actively advises and supports its customers worldwide through its dynamic and multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.
Stilla Technologies is backed by Illumina Ventures, Kurma Partners, TUS-Holdings, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and others. The company raised €20M ($22M) in a Series B round on Feb 11, 2020. This brings Stilla's total funding to €36.2M ($40.2M) to date.